Christopher G. ARMSTRONG,Kevin J. KIM,Lisa Maria Lucia PHAM,Eunhye PARK,Zhong ZHONG,Guanyi HUANG,Joseph C. WU,Sidney Paul ELMER,Viwat VISUTHIKRAISEE,Eithon Michael G. CADAG,Thomas Bernard FREEMAN,Pek
申请号：
US16737849
公开号：
US20200253920A1
申请日:
2020.01.08
申请国别(地区):
US
年份:
2020
代理人:
摘要：
This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3′；,4′；,5′；-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).
